Merck KGaA (FRA:MRK) Given a €100.00 Price Target at JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA (FRA:MRK) in a research note released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other equities analysts also recently issued reports about the stock. DZ Bank reissued a buy rating on shares of Merck KGaA in a report on Wednesday, August 14th. Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the company a buy rating in a report on Friday, September 6th. UBS Group set a €99.00 ($115.12) price target on shares of Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. Barclays set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the company a sell rating in a report on Wednesday, August 14th. Finally, Nord/LB set a €94.00 ($109.30) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. Merck KGaA presently has an average rating of Hold and an average target price of €100.94 ($117.38).

Shares of MRK stock opened at €99.02 ($115.14) on Thursday. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72). The firm has a 50-day moving average price of €94.83 and a 200 day moving average price of €94.65.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: What Are Cryptocurrencies?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.